[Looking for the now archived free BIOPHARMA®: Biopharmaceutical Products in the U.S. and European Markets databases?]
If you already recognize the high value of this IP, you can skip down to the "Bottom Line" section.
'Biopharma' is a >$1 trillion revenue/year industry using the now predominant broad definition; and is now a >$500 billion/year subset of the pharmaceutical/drug industry using the classic definition. The traditional 'Pharma(ceutical)' industry can be seen as genuinely becoming the 'Biopharma(ceutical)' industry as biopharmaceutical (using the classic biotech-grounded defintion) R&D and product revenue (and profits) now top that of chemically-derived/synthetic pharmaceuticals. With this, 'biopharma(ceutical)' will, if not already has, come to replace 'pharma(ceutical)' in common usage; clearly assisted by the global pharmaceutical industry, long publicly claiming to be 'biopharmaceutical.' .
Most of the world's leading (bio)pharmaceutical companies and trade groups long ago switched to using 'biopharmaceutical' to refer to and (re)brand themselves, their products and the industry. PhRMA has been prominently citing its members as and using the tagline/subtitle "America's Biopharmaceutical Companies" now since late 2005 (nearly 19 years); and "The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe." Along with the switch to using 'biopharma(ceutical),' 'pharma(ceutical)' and 'drug' are increasingly evoking negative perceptions and becoming legacy, deprecated, simply no longer used. For example, try to find any use by PhRMA at its Website or in its "flagship publication" and related "Industry Toolkits."
As with "pharma," the word "biopharma(ceutical)" has universal recognition and is used both as an adjective (e.g., biopharma R&D, products, companies, etc.) and a noun (e.g., biopharmaceuticals; "Biopharma," referring to the industry; also trend starting using 'biopharmas' to refer to companies). Google retrieved 26.3 million entries for the exact word "biopharma" (in quotes) and 101.0 million for "biopharma" (truncated) (on Jan. 18, 2024; these nos. vary daily). Use of "Biopharma(s)" to refer to companies is a new trend e.g., Google retrieved >30,000 entries in Sept. 2023 and 48,700 on Jan. 18, 2024. There are >600 publicly traded companies in the U.S. with "biopharma" in their name (SEC); and a total of >2,000 "biopharma" companies in the U.S. and ~4,000 worldwide (D&B). There are >2,650 "biopharma" (no truncation) company entries in Cruchbase and >800 in LinkedIn. Over 4,150 domain names contain, >1,100 names start with and >2,500 end with "biopharma."
BIOPHARMA Internet Dominance: Top-level domain ownership will provide your organization with exclusive and unbeatable "BIOPHARMA" Internet presence and
branding opportunities!
How much is it worth to your organization to be
recognized as a (or the) leading 'Biopharma' industry organization and/or be the top-level/first-used industry information source?
For example:
a) Brand your Web site, company, trade group, products, technologies, services, information resources, etc. as "BIOPHARMA." Be known as the
'biopharma' leader.
b) Be known as the leading source for information and promote your image and views
about the biopharmaceutical industry;
its products, technologies, public affairs, etc.; and/or otherwise
c) Greatly improve the impact and cost-effectiveness of your
public relations, marketing, advertising, lobbying, etc.
Such a prominent domain is its own perpetual advertising campaign.
The utility, impact, benefits and cost-effectiveness of a 'BIOPHARMA' domain will surely be much higher
than your usual episodic and transitory advertising, marketing, public relations, lobbying, efforts.
For a 1-time purchase at a fair price (open for bids now), this IP can remain yours forever.
There will be no better top-level industry-defining IP available. The only potential competition, "pharma.com," is tainted, was used by opioid epidemic-associated Purdue Pharma and is being sold as part of its bankruptcy proceedings (but who wants to be seen as "pharma" vs. "biopharma?")
An Established Brand: All trends and indicators point to increasing value of this IP. "Biopharma(ceutical)" is already a unversally-recognized brand worldwide, with much invested in this by the industry (easily $100s of milliions over the past 2 decades). Adoption of "biopharma(ceutical)" has been largely driven by nearly 2 decades of industry self-promotion redefining and (re)branding itself as "biopharmaceutical." This includes PhRMA annually spending a good portion of its multi-$100s million annual PR/advertising/lobby efforts supporting this, such as the multi-year "GoBoldly" campaign. Increasing common use and continuing worldwide 'biopharma(ceutical)'rebranding efforts by the industry will assure increasing value of this 'BIOPHARMA' IP for years to come!
Besides conveying a positive image associated with high-tech research, life-saving products, innovation, being 'bio(tech)', etc., unlike 'drug' and 'pharma(ceutical),' 'BIOPHARMA' is simply the best short term for the (bio)pharmaceutical industry and products. Alternatives, e.g., "biopharm," "biologics" and "biotech medicines," lack traction, have resisted catching on. Self-promotion as "biopharma(ceutical)" by an increasing number of companies and trade associations worldwide provides this IP with $millions worth of related promotion annually. The industry's good will, track record of innovation and successful responses to the Covid-19 pandemic continue to dramatically increase the value of 'biopharma' IP.
Value:
To perhaps(???) put the current commercial value of this IP in some context, the 'closest' (industry top-end-type)
published domain sales (in current $) include "drugs.com" which sold for >$1.2 million in 1999;
"pharmacy.com" for $2.9 million in 2008 and; Rx.com for $1 million in 2019.
BIOPHARMA.com surely has comparable or more and broader
utility and value than
such legacy 'drug' and 'pharmaceutical' transactional (all used for online prescription sales) domains.
Good "brandable" (blank slate) single word .com domains now commonly sell for this much, often more.
In contrast, "BIOPHARMA" is a truly exemplary established single word industry-defining, world-wide recognized brand with the
highest value and good will among all industries.
Biopharma.com has received a "fair market"
appraisal of
$1,000,000 (for domain investor/reseller, not the end-user market)
from AccurateAppraisals.com
As intangible assets and corporate investments, the domains are solid and reliable. Can you even imagine any loss of value or downsides to owning this IP? Most likely you are already envisioning $millions/year in benefits use of this IP could provide your organization. Ownership, even without use, is also an excellent option, whether as a high return investment or for strategic denial of use (e.g., Abbvie purchased "biosimilars.com" from me ~9 years ago and has never used it). Prudent use will add further to your domain's value.
Sales Status: The BIOPHARMA domains will be sold to the highest bidders in coming months. This includes buy-it-now sales to the first bidders in the owner's expected price range.
Contact the owner:
President Biotechnology Information Institute Rockville, MD 20851 E-Mail: domains@biopharma.com Phone: 301-424-0242 [most reliable contact method] |